Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction 2017-08-28 19:00
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial 2017-07-25 21:00
Resverlogix Randomizes First Patient in Taiwan/mainland China Portion of the Phase 3 BETonMACE Clinical Trial 2017-07-10 19:00
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success 2017-05-23 19:00
Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial 2017-05-15 22:11
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments 2017-01-23 20:00
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy 2016-08-30 00:53
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs 2016-07-22 04:17
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone 2015-10-26 19:00
Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital 2015-07-21 21:36
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink 2015-07-08 19:00
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority 2015-06-22 19:30
Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2015-06-01 19:30
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement 2015-04-27 19:00
Resverlogix Receives Two Patents for RVX-208 in China 2015-04-07 19:30
RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus 2014-09-02 20:30
Resverlogix Completes Dosing In ASSURE Clinical Trial 2013-04-18 19:00
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders 2013-04-08 19:00
1